Company profile: Cardior Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of non-coding RNA-based therapeutics and related tools for heart disease, including CDR132L (Phase 2) to halt and reverse cardiac remodeling after myocardial infarction; clinical trials in heart failure and MI; the CardiorHealth miR-132 PCR kit to measure circulating miR-132; and an H19 gene therapy approach targeting cardiac hypertrophy and heart failure.
Products and services
- CDR132L: An oligonucleotide-based, non-coding RNA therapeutic that inhibits the microRNA master switch to halt and reverse post–myocardial infarction cardiac remodeling, currently advancing through Phase 2 clinical trials
- CardiorHealth miR-132 PCR Kit: A PCR-based assay quantifying circulating microRNA-132 in blood of CDR132L-treated patients, supporting biomarker monitoring within the HF-REVERT Phase 2 clinical study
- Clinical Trials: Human clinical programs evaluating efficacy and safety of RNA-based therapeutics in heart failure and myocardial infarction, including Phase 2 assessments for post–myocardial infarction cardiac remodeling
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cardior Pharmaceuticals
Elsie Biotechnologies
HQ: United States
Website
- Description: Provider of RNA therapeutics and oligonucleotide discovery technologies, including a proprietary ultra-high throughput platform that evaluates oligonucleotide chemical space to optimize therapeutic candidates for activity, toxicity, and delivery, and P(V) chemistry technologies with novel reagents and processes to synthesize diverse oligonucleotide therapeutics with complete synthetic control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elsie Biotechnologies company profile →
Sirna Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology research and development focused on RNA interference (RNAi) for human disease therapy, creating RNAi-based therapies to ultimately treat patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sirna Therapeutics company profile →
SalioGen
HQ: United States
Website
- Description: Provider of non-viral Gene Coding technology enabling precise integration of large or multiple whole genes without double-strand breaks or guide RNA, and of programs including SGT-1001 for Stargardt disease, one-time genetic medicines for cystic fibrosis, CAR-T cell engineering for cancer and autoimmune diseases with tissue-specific integration, and therapies for inherited retinal diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SalioGen company profile →
PhaseRx
HQ: United States
Website
- Description: Provider of delivery solutions for siRNA and other macromolecular therapeutics for the treatment of orphan diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PhaseRx company profile →
Santaris Pharma
HQ: Denmark
Website
- Description: Provider of RNA-targeted therapy discovery and development using proprietary LNA chemistry through its LNA Drug Platform and Drug Discovery Engine; a privately held, clinical-stage biopharmaceutical company focused on highly specialized, targeted drug development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Santaris Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cardior Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cardior Pharmaceuticals
2.2 - Growth funds investing in similar companies to Cardior Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cardior Pharmaceuticals
4.2 - Public trading comparable groups for Cardior Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →